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Abstract
Acetylcholinesterase (AChE) is an essential enzyme that terminates cholinergic transmission by rapid hydrolysis of the
neurotransmitter acetylcholine. Compounds inhibiting this enzyme can be used (inter alia) to treat cholinergic deficiencies
(e.g. in Alzheimer’s disease), but may also act as dangerous toxins (e.g. nerve agents such as sarin). Treatment of nerve agent
poisoning involves use of antidotes, small molecules capable of reactivating AChE. We have screened a collection of organic
molecules to assess their ability to inhibit the enzymatic activity of AChE, aiming to find lead compounds for further
optimization leading to drugs with increased efficacy and/or decreased side effects. 124 inhibitors were discovered, with
considerable chemical diversity regarding size, polarity, flexibility and charge distribution. An extensive structure
determination campaign resulted in a set of crystal structures of protein-ligand complexes. Overall, the ligands have
substantial interactions with the peripheral anionic site of AChE, and the majority form additional interactions with the
catalytic site (CAS). Reproduction of the bioactive conformation of six of the ligands using molecular docking simulations
required modification of the default parameter settings of the docking software. The results show that docking-assisted
structure-based design of AChE inhibitors is challenging and requires crystallographic support to obtain reliable results, at
least with currently available software. The complex formed between C5685 and Mus musculus AChE (C5685NmAChE) is a
representative structure for the general binding mode of the determined structures. The CAS binding part of C5685 could
not be structurally determined due to a disordered electron density map and the developed docking protocol was used to
predict the binding modes of this part of the molecule. We believe that chemical modifications of our discovered inhibitors,
biochemical and biophysical characterization, crystallography and computational chemistry provide a route to novel AChE
inhibitors and reactivators.
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Introduction
The cholinergic system controls signals from nerve cells to
muscle cells or other nerve cells and is essential in all higher
organisms. The neurotransmitter acetylcholine 1 (ACh, Figure 1)
modulates the signaling in pre- and post-synaptic cells in the
synaptic cleft through its release and subsequent binding to the
cholinergic receptors. Acetylcholinesterase (AChE) is an essential
enzyme anchored to the cell membrane close to the cholinergic
receptors, which effectively terminates cholinergic transmission by
rapid hydrolysis of ACh [1]. AChE is found both in the peripheral
nervous system (PNS) and the central nervous system (CNS).
The crystal structure of AChE shows that the catalytic triad,
which is formed by serine, histidine and glutamate, is located at
the bottom of a narrow 20-A ˚-deep gorge that penetrates halfway
into the enzyme and widens close to its base [2,3]. The ligand-
binding cavity is lined with aromatic residues that account for
approximately 40 percent of the cavity surface. The entrance of
the gorge is termed the peripheral anionic site (PAS) as it was
initially believed to contain several negatively charged amino acids
due to its preference of binding cationic ligands [4]. However, the
crystal structure indicates that insufficient acidic amino acids are
located close to the ligand-binding cavity to support this
hypothesis. Instead it has been shown that aromatic residues
interact with cationic ligands [2,5]. A similar interaction pattern
can be seen at the catalytic site (CAS), and it is believed that ACh
initially binds to the PAS and then rapidly diffuses down to the
catalytic site [1,2].
Compounds that inhibit AChE are very powerful drugs and
toxins due to the essential function of the enzyme. In drug
discovery programs, AChE inhibitors are of great interest for
treatment of cholinergic deficiencies in the PNS (e.g. myasthenia
gravis) and CNS (e.g. Alzheimer’s disease). In contrast, some of the
most dangerous toxins currently known are AChE inhibitors, for
example the green mamba (Dendroaspis angusticeps) toxin fasciculin,
and the nerve agent sarin. In general, most AChE inhibitors mimic
ACh by possessing a quaternary amine or a basic nitrogen, hence
they are positively charged species at physiological pH and can
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Novem 1form cation - aromatic interactions with AChE. Examples of such
inhibitors are the drugs ambenonium 2 used to treat myasthenia
gravis, and donepezil 3 used to treat Alzheimer’s disease. In
addition, some inhibitors mimic the hydrolytic center (i.e., the
ester bond of ACh) by other functional groups (e.g., carbamates
and organophosphorus compounds; OPs). These compounds
inhibit AChE by forming a covalent bond with the catalytic
serine residue that is either reversible, as for carbamate containing
drugs, or irreversible, as for most OPs. The carbamate moiety has
been, and still is, a key functional group in medicinal chemistry
programs to develop drugs targeting AChE, for example the drugs
pyridostigmine 4 (myasthenia gravis) and rivastigmine 5 (Alzhei-
mer’s disease).
Many of the AChE inhibitors and lead structures known today
are derived from natural products, for example tacrine 6,
galanthamine 7 and hyperzine A 8 [6–8]. However, the molecule
that was further developed into donepezil 3 was discovered
through random screening of a compound collection [9,10].
Another important group of small organic compounds that
interact with AChE are oxime-based reactivators, such as
pralidoxime 9 (2-PAM), HLo ¨-7 10 and Ortho-7 11 [11–13].
These compounds can reactivate otherwise irreversibly inhibited
AChE (e.g., by OPs) via a nucleophilic attack that cleaves the
covalent bond between the enzyme and the OP adduct. The
chemical structures of the available antidotes are generally similar,
differing only in the number of pyridinium rings (mono or bis), the
length of the central linker, and the position of the nucleophilic
oxime on the pyridinium ring.
The urgent need for new drugs to treat cholinergic disorders like
Alzheimer’s disease [14], and the limited applicability of the
currently available antidotes to nerve agent intoxications (in terms
of blood-brain barrier permeability [15] and spectrum [16]) make
the research for new AChE inhibitors highly relevant. In the
design of novel compounds, structure-based design, such as
molecular docking, could be applied based on available crystal
structures of AChE in complex with inhibitors or reactivators.
Most crystal structures of AChE-ligand complexes that have
been obtained to date are for complexes of Torpedo californica AChE
(TcAChE) with natural products (e.g., galanthamine 7 [17] and
hyperzine A 8 [18]) or oximes with Mus musculus AChE (mAChE)
(e.g. Ortho-7 11 [19] and HI-6 12 [19,20]). In addition, donepezil
3 has been determined in complex with TcAChE [21]. On the
sequence level, the main difference between the catalytic sites of
the Torpedo and Mus musculus enzymes is the substitution of Phe330
in TcAChE by Tyr337 in mAChE, the latter being similar in this
respect to the Homo sapiens AChE (hAChE) [22].
Molecular docking simulations have been successfully used in
many medicinal chemistry projects making them valuable tools in
drug discovery [23]. However, reproducing the bioactive confor-
mation of AChE ligands, as determined by X-ray crystallography,
using molecular docking programs has proved to be problematic
[24–26]. The results of previously published studies were heavily
dependent on the type of ligand, the protein conformation, and
the presence of water. Despite these difficulties, molecular docking
of AChE ligands has been applied in numerous cases to explore
the AChE activity of synthesized compounds in terms of protein-
ligand interactions and structure-activity relationships (SARs)
based on pose predictions [27–30].
Most of the published structure-based virtual screens to identify
new AChE inhibitors have been based on simulations in which
enrichments of known inhibitors have been monitored [31–37]. In
general, these studies have found poor, or no enrichments of
compounds binding to AChE [32–36], illustrating the challenges
associated with docking of AChE inhibitors. Further, among the
cases where some enrichments have been detected [32,33,35]
there is no agreement regarding the optimal docking program.
However, a successful structure-based virtual screen of commer-
cially available compounds using flexible docking that resulted in
the identification of novel AChE inhibitors has been reported [31].
In this paper, we present an in vitro high throughput screen
(HTS) of a large collection of molecules intended to identify novel
AChE inhibitors. The binding modes of a selection of the
discovered hits have been determined by X-ray crystallography
and reproduced by molecular docking simulations. The potential
of using the hits as lead structures for AChE inhibitors and
reactivators in drug discovery programs is also discussed.
Figure 1. Chemical structures of ligands that bind to AChE. The native substrate acetylcholine 1; inhibitors, ambenonium 2, donepezil 3,
pyridostigmine 4, rivastigmine 5, tacrine 6, galanthamine 7 and huperzine A 8; nerve agent antidotes, 2-PAM 9, HLo ¨-7 10, ortho-7 11 and HI-6 12.
doi:10.1371/journal.pone.0026039.g001
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High throughput screening and determination of IC50
values
A chemical library consisting of 17 500 substances was screened
using the colorimetric Ellman assay and recombinant hAChE. The
hydrolysis of acetylthiocholine iodide was monitored and the
average slope of the positive controls was set to 100% activity. At
an assay concentration of 50 mM, 124 compounds reduced the
enzymatic activity of hAChE by at least 70% in the single replicate
assays. To confirm the activity of the hits, the half-maximal
inhibitory concentration (IC50) was determined for 30 compounds
(Set 1, Table 1). Molecules in Set 1 were selected to represent the
chemical space according to a Principal Component Analysis
(PCA) of the hits’ structural and physicochemical features (see
section Chemical space of AChE inhibitors, below). The IC50
determinations confirm that the 30 compounds in Set 1 are
indeed AChE inhibitors, with IC50 values ranging from 0.29–
82 mM (Table 1 and Figure 2). Furthermore, a second data set (Set
2) of 30 substances showing activities of 065% in the single
replicate assays was selected from neighboring positions in the
established chemical space. Quadruple sampling at a ligand
concentration of 50 mM confirmed that the substances in Set 2
were non-binders, but one of the substances inhibited AChE by
71%, close to the original cut-off value, and had an IC50 value of
48 mM (see File S1).
Crystallographic studies of selected hits
The number of hits prompted us to investigate the success rate
of complex formation using a standardized protocol with no
compound-specific optimization of soaking conditions. In total, 36
hits were subjected to complex-formation trials where the
standardized protocol (see Materials and Methods) was reproduced
to the best of our ability. To facilitate this approach, the Mus
musculus AChE (mAChE; 88% sequence identity and all residues in
the active site identical with the human enzyme) was used. The
low salt and neutral pH conditions used for the crystallization of
mAChE (see Materials and Methods) and the corresponding crystal
packing has proven robust and suitable for studies of PAS binding
ligands [20,38].
Typically, several soaking attempts were required before a
crystal displaying satisfactory diffraction was identified, hence
there were more than 200 individual soaking trials in total.
Interestingly, one compound resisted our efforts and repeatedly
cracked the crystals during the soaking procedure, possibly
indicating that the ligand induces a structural change that is
incompatible with the crystal packing. In total, 35 data sets were
collected and after initial refinements, electron density features
that could be attributed to a small molecule were found in nine
datasets. These datasets were subjected to complete structural
refinement, during which two were discarded due to difficulties to
accurately and conclusively build the ligand in the electron density
maps. Out of the original 36 compounds, structures for seven were
finalized. One of the determined structures revealed that a
complex between mAChE and a degradation product of the
compound present in the chemical library had been formed. This
complex is not further discussed herein.
The crystal structures of the complexes formed by mAChE and
the six compounds (Figure 3) were refined to a resolution ranging
from 2.3 to 2.8 A ˚. The IC50 of the successfully determined
compounds ranged between 0.2 and 36 mM (Table 2). Overall, the
structures are similar regarding protein backbone, side chains (the
amino acids with the largest variations in the active site gorge were
Tyr337 and Tyr72 with maximum atom deviations of 2.15 A ˚ and
1.82 A ˚, respectively), and binding site occupancy of the ligands.
One of the complexes (C5685NmAChE) differed slightly from the
others as Tyr337 and the CAS binding portion of the ligand were
disordered. The structures show extensive interactions between the
ligands and amino acids in the PAS (Table 3). The ligands stack
with Tyr341 and/or Trp 286 and a direct hydrogen bond between
the ligand and main-chain nitrogen of Phe295 is present in five
cases and in one structure the hydrogen bond is bridged by a water
molecule. One of the compounds is PAS specific (C5231), while
the remaining ligands have additional interactions with Tyr124,
Tyr337 and Trp86 in the active site gorge and the catalytic site
(Table 3). A SAR analysis based on the structures and their
corresponding IC50 values showed, as expected, that larger
molecules with favorable interactions in both PAS and CAS (i.e.,
C7653 and C7645) give a stronger inhibition than ligands of
moderate size and fewer interaction points (i.e., C7491 and
C5231). The complex between mAChE and the racemate C5685
(C5685NmAChE Figure 4) is a representative structure for the
Table 1. IC50 values of the representative set of active
compounds identified in the HTS.
Set 1
No. Compound IC50
1 (mM)
1 A6035 0.2960.02
2 A7966 0.3860.02
3 A9007 1.260.1
4 A7686 1.460.1
5 A5388 1.560.3
6 A7528 1.860.1
7 A5315 1.960.4
8 A7372 1.960.7
9 A7998 2.960.5
10 A5846 3.160.9
11 A6623 3.361.8
12 A6164 3.560.9
13 A7175 3.561.2
14 A5918 3.660.8
15 A9005 3.960.3
16 A5130 5.360.3
17 A5744 6.064.3
18 A5922 6.260.8
19 A5332 6.863.0
20 A7988 7.160.6
21 A6144 11.660.9
22 A6386 13.362.2
23 A6676 14.161.4
24 A6659 25.765.0
25 A5319 30.261.3
26 A6435 40.8616.5
27 A5320 43.4612.0
28 A7124 47.6627.6
29 A6642 50.963.4
30 A7695 81.8623.9
1Mean 6 standard deviations of 2–4 determinations.
doi:10.1371/journal.pone.0026039.t001
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unique features, and will therefore be described in detail. The
crystal structure of C5685NmAChE was refined to a resolution of
2.4 A ˚ (Table 4), showing an overall structure that is very similar to
the apo structure of mAChE (pdb entry code: 1J06 [38]) with a
main chain root-mean-square deviation (RMSD) of 0.13 A ˚.N o
major structural changes of the protein backbone were evident. As
for other structures of mAChE, the loop region including residues
258–264 could not be modelled from the acquired data.
Moreover, the electron density around residue 495 is weak,
resulting in a few outliers in the Ramachandran plot. The electron
density maps convincingly define the binding site of C5685, with
the substituted phenyl-ring system stacked between the phenol-
ring of Tyr341 and the indole-ring of Trp286 (Figure 4A and 4B).
The electron density map suggests that the N-methyl groups are in
a plane with the aromatic system whereas the two oxygen atoms of
the nitro group are out of the plane, thus presumably preventing a
clash with the N-methyl groups. This allows a 3.0 A ˚ hydrogen
bond between the two nitro oxygens of C5685 and the main chain
nitrogen of Phe295 (Figure 4B). The 2-methoxy group is found in
the vicinity of the side chain of Asp74, forming a 2.9 A ˚ intra-
molecular hydrogen bond with the amide nitrogen of the linker.
Moreover, the phenolic oxygen of Tyr124 is found at distances of
3.2 A ˚ from the methoxy oxygen presumably allowing formation of
a hydrogen bond between these groups (Figure 4B). In this
particular structure, the electron density map of the Tyr337 side
chain is disordered and was refined for two conformers (Figure 4).
Only one of the conformers was present in the five other structures
(corresponding to ATYR in the pdb-file). The N-ethylpyrrolidine
moiety of C5685, containing the chiral carbon, is directed towards
the CAS of mAChE but it could not be unambiguously modelled
in the electron density map and was therefore omitted from the
final structure. However, residual positive density features in the
vicinity of the indole ring of Trp86 likely accounts for the
unmodelled parts of the molecule (Figure 4A). Moreover, as often
observed in structures of mAChE, a strong residual positive density
feature is found close to Ser203Oc.
Chemical space of acetylcholinesterase inhibitors
The AChE inhibitors discovered in the screening campaign are
chemically diverse, with molecular weights ranging between 234
a.u. and 596 a.u., logP (o/w) values between 21.16 and 8.14, and
0 to 12 rotatable bonds. The broad chemical diversity is further
illustrated by a PCA of the structural and physicochemical features
of the hits. Five principal components (PCs) proved significant:
PCs 1 and 2 related mainly to size and hydrophobicity,
respectively; PCs 3 and 4 related to flexibility and charge (positive,
neutral or negative); and PC5 related to electronic properties
associated with halogens and aromatic elements (see File S1). The
124 hits distributed evenly in the chemical space formed by these
five PCs (Figure 5 and File S1). The 30 selected hits with
determined IC50 values (Set 1) confirmed that AChE inhibitors
populated the established chemical space as no false positives were
detected. No correlations were detected between the calculated
structural and physicochemical features of the compounds and
their inhibitory effect.
The hits for which crystal structures were successfully
determined only covered part of the chemical space although
the 36 hits that were subjected to complex-formation trials
completely spanned the chemical space (Figure 5 and File S1). The
ligands of the determined complexes showed a moderate span in
size, hydrophobicity and electronic properties (i.e., PC1, PC2, and
PC5) whereas they were relatively more flexible and lacked
negative charges and thus did not spread completely in PC3 and
PC4.
A selection of previously identified AChE inhibitors and
reactivators (2, 3, 6, 7 and the scaffolds of 9–11 without the
oxime functionality) were projected into the established chemical
Figure 2. Dose-response curves for a subset of hits. In the figure,
the mean 6 standard deviation of 2–4 determinations is plotted.
doi:10.1371/journal.pone.0026039.g002
Figure 3. The chemical structures of the AChE inhibitors. The compounds C5231–C7653 were identified as hits in the HTS and their bioactive
conformations were determined in complex with mAChE by X-ray crystallography.
doi:10.1371/journal.pone.0026039.g003
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different and significantly larger chemical space (PC1 vs. PC2, and
PC3 vs. PC4, Figure 5 and File S1).
Molecular docking of acetylcholinesterase inhibitors
We set out to develop a general docking protocol for predicting
binding modes of AChE inhibitors, which could be used for
structure-based design in drug discovery projects. The ligands of
the determined protein-ligand complexes (Figure 3) were docked
to the protein conformation observed in the C5685NmAChE
protein crystal structure, where the conformation of Tyr337 with
the highest apparent occupancy was represented. In addition, 12
water molecules were explicitly included during the docking
simulations, selected based on analysis of conserved water
molecules in the binding site of mAChE.
The ability of three docking software packages (FRED [39],
Glide [40] and GOLD [41]) to regenerate the bioactive
conformations of the ligands was evaluated, deeming a docking
pose with an RMSD value less than 2.0 A ˚ compared to the pose
found in the crystal structure to be acceptable. The investigated
packages differ in their treatment of ligand and protein flexibility
as well as how the docking poses are generated in the binding site
of the protein (for details, see references for the respective
packages). When default parameter settings were used, all three
packages generated poor pose predictions (Table 5). However,
Glide had the best success rate, generating acceptable poses for
two of the seven ligands. It should be noted that adjustments of the
dimensions used to define the binding site were made to allow
placement of the ligands in any part of the active site gorge during
the docking simulations.
To improve the performance of the docking software, modified
parameter settings were applied in Glide, where the number of
poses included in the post-docking force-field minimization and
the number of poses to output was increased. Ensembles of poses
were thereby generated, including acceptable poses for all ligands.
However, the acceptable poses were not found among those top-
ranked by the scoring function used for docking in standard
precision mode in Glide, GlideScore SP (Table 6). All poses were
therefore re-scored using available scoring functions in GOLD
(ASP and GoldScore), and FRED (Chemgauss2, Chemgauss3,
Chemscore, OEChemscore, PLP, Screenscore, Shapegauss and
Zapbind) as well as with DrugScore. Chemgauss3 proved to be the
best performing scoring function, top-ranking acceptable poses for
five of the seven ligands (Table 6). When the number of total
acceptable poses among the five and ten top ranked by the
different scoring functions were examined, PLP was the superior
scoring function resulting in 65% of the poses with RMSD value
less than 2.0 A ˚ compared to the pose found in the crystal structure
(Figure 6). The worst performing scoring functions were
Chemgauss2, Chemscore and OEChemscore top-ranking accept-
able poses for only one of the six ligands and less than 30%
acceptable poses ranked in the top five (Table 6 and Figure 6). The
lowest RMSD-values among the five and ten highest ranked
docking poses by the twelve scoring functions can be viewed in File
S1. Based on our results, the choice of scoring function will depend
on whether several docking poses will be extracted for post-
processing and re-scoring. If only the top ranked pose is to be
extracted, Chemgauss3 appears to be the best choice, while PLP
seems to be a better option if further processing of multiple poses is
intended.
The generated poses for the C5685 enantiomers were evaluated
to investigate possible binding modes of the part of the molecule
that was not modeled in the X-ray crystal structure (i.e., the N-
ethylpyrrolidine moiety). Acceptable poses were obtained for both
C5685 (R) and C5685 (S), and manual inspection of the docking
poses revealed that a number of conformations of the N-
ethylpyrrolidine substructure had been generated. To investigate
if the binding modes proposed by Glide are structurally relevant,
the local strain energies of the ligand conformations were
calculated. For each enantiomer, three poses with low local strain
energy were selected as representative poses (Figure 7). The local
strain energies of these poses are of the same order of magnitude as
for the ligand conformations of the five other included protein-
ligand complexes.
Discussion
AChE inhibitors as chemical leads for drug discovery
The primary goals of the present study were to identify novel
AChE ligands using HTS of a chemical library and to evaluate if a
combination of crystallography and attentive molecular docking
can be used to design drugs targeting AChE. While numerous
inhibitors and their crystal structures have been reported
previously, the 124 hits from the screening campaign reported
herein were identified from a large, unbiased library of 17 500
compounds. The identified hits encompass large chemical diversity
(including for instance small, large, polar, non-polar, rigid, flexible,
acidic and basic compounds) and they are structurally different
from the AChE inhibitors derived from natural products as well as
the known reactivators. Current drugs targeting AChE, e.g., to
Table 2. IC50 values of the hits for which crystal structures
were successfully determined.
Compound IC50
1 (mM)
C7653 0.2060.05
C7643 0.5460.03
C5685 1.360.1
C6905 2.060.1
C7491 21.461.7
C5231 36.066.3
1Mean 6 standard deviations of 2–5 determinations.
doi:10.1371/journal.pone.0026039.t002
Table 3. Interactions patterns observed in the determined
complexes between the ligands and the corresponding
residues in mAChE.
1
Inhibitor
Residue C5231 C5685 C6905 C7491 C7643 C7653
Trp286 x x x x x x
T y r 3 4 1 xxxxxx
Phe295 x x x x x x
2
T y r 1 2 4 -xx-x-
Tyr337 - - x x - x
Trp86 - -
3 --xx
1x indicates presence of an interaction defined by close contacts (pair-wise
heavy atom distance #3.5 A ˚).
2The interaction is mediated by a water molecule.
3Residual positive density features were found within the cut off distance.
doi:10.1371/journal.pone.0026039.t003
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effects, and/or low efficacy [14], warranting searches for new
chemical skeletons that could have different pharmacodynamic
and pharmacokinetic profiles. Our hits could serve as chemical
leads in such drug discovery programs. Furthermore, the
discovered hits have different chemical skeletons from the
currently used nerve agent antidotes, and could be used in the
development of antidotes with increased blood-brain barrier
permeability and a broader reactivation spectrum.
One of the challenges associated with this work was to obtain
high-resolution structural data for a sufficient number of hits to
obtain information regarding binding modes that could provide
starting points for docking-assisted structure-based design. Crys-
tallographic study of AChE complexes often involves optimization
of the ligand occupancy through spectroscopic techniques or the
collection of several datasets under varying conditions [20,38,42].
Optimization of the ligand occupancy is advantageous and feasible
in investigations of a limited number of complexes. However, the
number of hits we identified prompted a different approach,
relying exclusively on a standardized protocol.
Starting with a collection of 36 hits, over 200 soaking
experiments were performed, resulting in the collection of 35
datasets and seven finalized structures, corresponding to an overall
success rate of 19%. The structural analysis of the ligands shows
that their non-covalent interactions with AChE have several
common features. All crystal structures show extensive interactions
between the ligand and the PAS region of AChE. One ligand is
PAS–specific, whereas the remaining structures have moieties that
extend towards the catalytic site and the indole ring of Trp86. Of
the compounds for which AChE-ligand complexes have been
previously determined, donepezil 3 is chemically most similar to
our structurally determined AChE inhibitors (cf. 3 and green
markers in Figure 5). Comparison of the crystal structures
C5685NmAChE and 3NTcAChE (pdb entry code: 1EVE [21])
shows that the overall protein structures are similar and that the
ligands occupy the same portion of the binding site. The PAS-
binding parts show similar molecular interaction patterns,
including the direct or water-mediated hydrogen bond between
the ligands and the main chain nitrogen of Phe295. The main
differences in structure and molecular interaction patterns can be
Figure 4. The mAChE binding site of C5685 determined by X-ray crystallography. The final 2|Fo|2|Fc| (contoured at 1s) electron density
maps of C5685 (yellow) and the two conformers of Tyr337 in mAChE (cyan) (A). Close-ups showing putative hydrogen bonding interactions (B). The
binding site of C5685 at the PAS of mAChE; in (C), the apo mAChE structure (grey) has been superimposed on C5685NmAChE, and in (D) the Connolly
surface is visualized (cyan carbon; dark blue nitrogen; red oxygen).
doi:10.1371/journal.pone.0026039.g004
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Phe330 in TcAChE). Molecular docking simulations were used to
investigate possible binding modes of the N-ethylpyrrolidine
moiety of C5685. Several plausible binding modes were detected
and no distinction could be made between the two enantiomers in
this respect; low RMDS-poses that represent structurally relevant
binding modes were generated for both C5685 (R) and C5685 (S).
Reproducing the bioactive conformations of six ligands
(determined by crystallography) using molecular docking proved
to be difficult. Applying the default parameter settings, no docking
program could reproduce the experimentally determined binding
modes in a satisfactory manner. One challenge appears to be the
large binding site with similar physicochemical features of PAS
and CAS, leading to inaccurately predicted binding modes in
which the ligands are rotated 180 degrees. By modifying the
docking parameters then re-scoring the output poses using 12
scoring functions, acceptable results were obtained. The results
from the re-scoring showed that the latest version of Chemgauss
(i.e. Chemgauss3), a Gaussian-based empirical model that include
a solvatisation term, gave good results together with PLP. The
scoring functions that are based on the Chemscore scoring
functions (Chemscore, OEChemscore and Glidescore) seem to
give less reliable results. It should be noted that the general
applicability of these results needs to be investigated. Previous
studies involving re-docking of natural products with known
bioactive conformations have shown that the type of ligand, the
protein conformation and the presence of water are important
factors [24–26]. In general, we believe that molecular docking of
ligands to AChE for predicting the binding modes is very
challenging, leading to large uncertainties in the results, and thus
must be accompanied by X-ray crystallography to experimentally
determine the bioactive conformation of several ligands repre-
senting the chemical skeleton of interest.
Future design of nerve agent antidotes
It is important to emphasize that the hits identified and
characterized in the present study were selected from a library
composed of drug-like molecules. In contrast to reactivators (i.e.
nerve agent antidotes), they lack reactive nucleophilic moieties,
and are therefore unable to restore the function of AChE inhibited
by nerve agents (OP-AChE). Thus, the criteria, experimental data
and techniques required to design reactivating antidotes using
these hits need to be identified and developed. The efficacy of a
reactivator is described by its bimolecular reactivation constant
(kr2), which depends on both the affinity (dissociation constant, KD)
between the antidote and the inhibited enzyme, and the rate of the
chemical reaction (kr). The determination of kr2 has a limited utility
in rational design of new reactivators since only molecules that
contain a nucleophilic moiety and show reactivation activity will
result in kr2 values that can guide further molecular development.
Thus, we are currently developing activity-independent methods
based on time correlated single photon counting spectroscopy in
order to determine the binding affinity of candidate molecules to
inhibited AChE.
Based on our hits and determined crystal structures (Figure 3),
we have identified chemical entities that interact with the PAS, the
active site gorge, or the CAS. Our approach will now be to use
these chemical entities in statistical molecular design [43] to
construct small sets of compounds formed by combinations of
PAS-, gorge-, and CAS-specific fragments that can be submitted
for synthesis and explored for binding affinity of OP-AChE to
identify suitable chemical leads for antidotes. We believe that a key
property of the nucleophile is an intrinsic mobility that allows a
conversion to the transition state for reactivation while preventing
entrapment in an unproductive conformation. The design of the
positioning of the nucleophile on the chemical leads will be assisted
by molecular docking based on the proposed protocol followed by
molecular dynamic simulations.
Conclusions
In presented study, in vitro screening of 17 500 drug-like
molecules resulted in 124 hits that inhibited the enzymatic activity
of AChE by more than 70%. Re-testing at several ligand
concentrations confirmed their activity, with IC50 values of 0.20–
82 mM. The discovered hits displayed a wide chemical diversity
and were structurally different from known inhibitors and
reactivators. In an extensive crystallization effort we successfully
determined the 3D structures of seven of these ligands in complex
with mAChE. All structures showed extensive interactions between
the ligand and amino acids in PAS and five of the structures had
additional interactions with the active site gorge and CAS.
Reproduction of the bioactive conformations of the ligands using
molecular docking by Glide required modification of the
molecular docking protocol. The multiple crystal structures
provided a robust test of the scoring functions used for re-scoring,
for which Chemgauss3 and PLP, proved to be superior for this
data set. The results show that structure-based design of AChE
inhibitors and reactivators using molecular docking simulations
needs to be assisted by crystallography to obtain reliable results.
Table 4. Data collection parameters and refinement statistics.
Data collection C5685NmAChE
PDB entry code 4A23
Space group P212121
Unit cell dimensions (A ˚) 78.96111.86227.0
Resolution range (A ˚) 19.64–2.40 (2.4–2.53)
Total number of reflections 585242 (85350)
Unique reflections 79036 (11407)
Completeness (%) 99.6 (99.8)
Multiplicity 7.4 (7.5)
Rmerge
1 0.053 (0.358)
Mean(I)/sd(I) 25.8 (7.5)
Refinement
R-factor
2/Rfree
3 (%) 17.5/20.9
B-factor
4 (A ˚2) 48.24
Number of water molecules 871
RMSD from ideal values
Bond lengths (A ˚) 0.008
Bond angle (u) 1.135
Ramachandran plot %/no. of residues
Most favoured regions 1030 (97.2%)
Allowed regions 26 (2.5%)
Residues in disallowed regions 4 (0.4%)
5
1Rmerge=(g|I2,I.|)/gI, where I is the observed intensity and ,I. is the
average intensity obtained after multiple observations of symmetry related
reflections.
2R-factor=(gIFo|2|FcI)/gFo, where Fo are observed and Fc calculated structure
factors.
3Rfree uses 2% randomly chosen reflections defined in Brunger [77].
4B-factor is the mean factor for protein main chain A/B.
5Corresponds to Ala 342, Ala542, Lys496 and Ser497of the B monomer.
doi:10.1371/journal.pone.0026039.t004
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of binding in PAS and the developed docking protocol was used to
predict the binding modes of the C5685 enantiomers at CAS,
which were not modeled in the X-ray crystal structure. According
to the molecular docking simulations both C5685 (R) and C5685
(S) will bind to AChE as acceptable binding poses were obtained
for both.
The design of AChE inhibitors and nerve agent antidotes as
outlined herein is an experimentally challenging drug discovery
project for which mechanistic insights together with structural,
biochemical and biophysical techniques are required as founda-
tions for (and to validate) computational techniques such as
molecular docking and dynamic simulations. We believe that
chemical modifications of our discovered inhibitors, biochemical
and biophysical characterization, crystallography and computa-
tional chemistry provide a route to novel AChE inhibitors and
potentially also to reactivators.
Materials and Methods
High throughput screening
The screening was performed at the Umea ˚ Small Molecule
Screening Facility currently incorporated in the screening platform
of the Laboratories for Chemical Biology, Umea ˚ (LCBU) [44].
Figure 5. The chemical space of the identified AChE inhibitors. The chemical space was established by PCA of the physicochemical properties
of the 124 hits (grey dots) that were identified in the HTS. The first and second PCs describe the size and polarity of the molecules (A), while the third
and forth PCs illustrate the molecule’s distribution related to charge and flexibility (B). The hits for which crystal structures were successfully
determined are shown in green and the known AChE inhibitors that were projected into the chemical space are shown in red (2, 3, 6, 7, and 9–11;
see Figure 1 for chemical structures). Hotelling’s T2 (95%) is visualized as circled solid line.
doi:10.1371/journal.pone.0026039.g005
Table 5. RMSD values of poses generated by molecular
docking simulations of AChE inhibitors using default
parameter settings.
RMSD (A ˚)
1
Docking
software C5231 C5685 (R) C5685 (S) C6905 C7491 C7643 C7653
FRED 6.83 4.14 3.89 3.67 3.07 2.44 10.49
Glide 6.79 1.14 7.83 2.63 3.69 1.13 2.04
GOLD
2 8.53 8.16 2.50 4.89 3.87 2.77 1.77
1The RMSD values of the acceptable poses (less than 2.0 A ˚) are indicated in
bold.
2The RMSD value (A ˚) of the highest ranked pose by GoldScore is reported from
the GOLD docking.
doi:10.1371/journal.pone.0026039.t005
Table 6. RMSD values of the highest ranked docking poses
after re-scoring of poses generated using the modified
parameter settings in Glide.
1
RMSD (A ˚)
2
Scoring
function C5231 C5685 (R) C5685 (S) C6905 C7491 C7643 C7653
ASP
a 7.02 3.75 3.75 1.12 3.13 1.54 1.35
Chemgauss2
b 6.92 3.41 1.35 3.17 4.59 11.24 2.04
Chemgauss3
b 6.84 1.14 1.02 1.40 3.02 0.83 1.46
Chemscore
b 6.66 6.18 6.07 1.51 8.55 2.18 2.02
DrugScore 6.89 8.26 1.35 1.08 5.02 2.20 2.68
GlideScore SP
c 6.79 1.12 3.97 3.23 3.02 2.20 2.04
GoldScore
a 7.05 8.39 7.83 0.81 8.90 1.94 2.05
OEChemscore
b 8.73 6.20 6.07 1.17 5.02 11.68 2.05
PLP
b 6.84 1.00 1.02 1.16 9.09 1.19 2.05
Screenscore
b 7.02 6.16 6.94 1.51 2.77 1.19 1.88
Shapegauss
b 8.23 8.26 2.95 1.51 4.41 0.83 2.32
Zapbind
b 6.93 4.03 2.69 2.41 1.46 0.90 1.20
1Scoring functions are available in:
aGOLD,
bFRED and
cGlide.
2The RMSD values of the acceptable poses (less than 2.0 A ˚) are indicated in
bold.
doi:10.1371/journal.pone.0026039.t006
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previously described methods [45,46]. The enzymatic activity was
measured using the Ellman assay [47] adapted to a 96-well format.
The final assay volume was 200 mL and all measurements were
performed in 0.2 mM 5,59-Dithiobis(2-nitrobenzoic acid) and
1 mM acethylthiocholine iodide in 0.1 M phosphate buffer
pH 8.0. The chemical collection comprising 17 500 unique
compounds accessed by LCBU has been purchased from Chem-
Bridge (San Diego, CA) [44]. Stock solutions were prepared in
DMSO and transferred to the assay plate using a Biomek NC
robotic system (BeckanCoulter). The enzymatic reaction was
monitored for 120 seconds using an Infinite M200 plate-reader
(Tekan) at a ligand concentration of 50 mM and temperature of
20uC. Each plate contained 80 samples, 14 positive controls and
two negative controls. The average slope (typically 0.4860.1 dA/
min) obtained from assays with 14 positive controls was set as
100% activity. Substances reducing the activity by at least 70%
were scored as hits. IC50 values were determined using a similar
approach, starting with freshly prepared solution of the inhibitor.
For each inhibitor, the enzymatic activity was determined at eight
concentrations selected to produce a dose-response curve that was
subsequently analyzed using Prism [48].
Selection of Sets 1 and 2
Set 1 includes compounds that were identified as hits in the HTS,
foreach ofwhicha fulldose responsecurvewasobtained toverifyits
inhibitory activity (and thus detect potentially false positives). This
set was selected manually from the chemical space spanned by the
hits (i.e. the five significant PCs; Figure 5 and File S1) in two rounds
(20 plus 10 compounds). The selection was made to achieve an even
distribution in the chemical space without including compounds
with extreme values for any of the significant PCs. Set 2 includes
compounds that showed no activity in the HTS but had similar
structural and physiochemical features to the hits and was used to
investigate the degree of false negatives. Set 2 was selected in a
similar fashion to Set 1, based on predicted scores resulting from
projection of compounds with 065% activity in the HTS into the
chemical space of the AChE inhibitors. Set 2 was also selected in
two rounds (20 plus 10 compounds). All of the included inactives
occupied the same chemical space as the AChE inhibitors, that is,
they exhibited similar chemical features as the hits.
Generation, collection and refinement of crystal
structures
mAChE was crystallized as previously described [45]. Grains of
the ligand were added to a soaking solution consisting of 30% (v/v)
polyethylene glycol 750 monomethylether, 100 mM HEPES
pH 7.0 until saturation was reached and a precipitate was formed.
After approximately 15 minutes the precipitate was removed by
centrifugation and the soaking solution was added in four portions
of 2 mL to a crystal of mAChE. The soaking was performed during
a time-frame of five minutes and the crystal was incubated for an
additional five minutes prior to flash-freezing in liquid nitrogen. X-
ray diffraction data were collected at the MAX-lab synchrotron
(Lund, Sweden), beam lines I911-2 and I911-3, equipped with
MAR Research CCD detectors. The images (at least 140) were
collected using an oscillation angle of 1.0u per exposure. The
intensity data were indexed and integrated using XDS [49] and
scaled using Scala [50]. The C5685NmAChE structure was
determined using rigid-body refinement starting with a modified
Figure 6. The proportion of acceptable poses highly ranked by each of the scoring functions. The percentage of poses with RMSD values
less than 2.0 A ˚ compared to the pose found in the crystal structure among the highest ranked (black), among the top five (white) and among the top
ten poses (grey) is presented. Since there were few acceptable poses of C5231, the ligand was only considered in the calculation of the percentage
among the highest ranked.
doi:10.1371/journal.pone.0026039.g006
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crystallographic refinement was performed using the Phenix
software suite [51]. The presence of ligands in the AChE binding
site of the AChE crystals was estimated based on the initial
2|Fo|2|Fc| and |Fo|2|Fc| omit maps, and only protein-ligand
complexes where ligand occupancies were detected were subjected
to further refinement. Several rounds of refinement were
performed, alternating with manual rebuilding of the model after
visualizing the 2|Fo|2|Fc| and |Fo|2|Fc| electron density maps
using COOT [52]. The quality of the final model was evaluated
using PROCHECK, WHATCHECK and RAMPAGE [53–55]
and the figures were constructed using PyMol [56].
Chemical space of acetylcholinesterase inhibitors
The structural and physicochemical features of the 17 500
compounds in the chemical library were described by 2D
molecular descriptors using MOE [57]. A complete list of
descriptors is shown in File S1. The properties of the hits from
the HTS were used to extract the main principal properties of the
AChE inhibitors, and hence form the chemical space they
spanned, using PCA. PCA is an unsupervised projection method
in which systematic variation in a data set is extracted into a few
variables; Principal Components or PCs [58]. The PCs are linear
combinations of the original variables and are uncorrelated to
each other, as described by Equation 1.
X~t1p1
’zt2p2
’zt3p3
’z...ztApA
’zE~TP’zE ð1Þ
where X is the original data matrix (here the chemical features’ of
the compounds), A is the total number of extracted PCs, and E is
the residual matrix. The new latent variables, the t scores, show
how the compounds relate to each other, while the p loadings
reveal the importance of the original chemical features for the
patterns seen in the scores. The number of significant components
was determined according to a Scree-plot (eigenvalues vs. PCs, see
File S1). The data were mean-centered and scaled to unit-variance
prior to PCA. The analysis was performed using SIMCA [59] and
Evince [60]. Model statistics are found in File S1.
Projection of known AChE ligands
To monitor and assess the novelty of the chemical features of
the discovered hits, the positions of 2, 3, 6, 7, and 9–11 were
projected into the chemical space established by the AChE
inhibitors. The comparison with 9–11 was based on the scaffolds
of the reactivators, and the oxime functionality was therefore
removed prior to calculating the molecular descriptors.
Molecular docking
The atomic coordinates of six of the protein-ligand complexes
determined by X-ray crystallography (C5231, C5685, C6905,
C7491, C7643 and C7653) were considered in the docking study.
All dockings were performed to one representative protein crystal
structure (C5685NmAChE) as the objective was to generate a
general docking protocol that could be used to predict the binding
poses of new ligands. Default settings were used in the
computations unless otherwise stated.
Ligand and protein preparation. The 3D atomic
coordinates of the ligands used as input in the docking
simulations were rebuilt from SMILES in MOE [57] using the
MMFF94x force field. Both of the enantiomers of C5685 were
included in the docking attempts, resulting in a total of seven
ligands. The ligand protonation states were set manually, assigning
amines positive charges while anilines were considered neutral,
rendering six out of seven ligands positively charged. All ligands
were docked to the C5685NmAChE protein crystal structure
(refined to a resolution of 2.4 A ˚), where the most populated
conformation of Tyr337 was selected (ATYR337) with an
apparent occupancy of 0.57. This conformation was selected
since it is similar to the conformations observed in the remaining
protein-ligand complexes included in the study. Twelve conserved
hydration sites were identified in mAChE by manual inspection of
water molecules present in 18 crystal structures available from the
RCSB protein data bank [61] (pdb entry codes: 1KU6, 1N5M,
1Q84, 2GYU, 2GYV, 2GYW, 2H9Y, 2HA0, 2HA2, 2HA3,
2HA4, 2JEZ, 2JF0, 2JGE, 2JGL, 2WHR, 3DL4 and 3DL7) and
the structures determined herein. The results from this analysis
were transferred to the C5685NmAChE protein crystal structure
where all water molecules were removed from the coordinate file
except for W3, W9, W15, W46, W84, W85, W127, W145, W176,
W229, W339 and W729. The protein preparation wizard
implemented in Maestro [62] was used to prepare an all-atom
protein model and to optimize the hydrogen bond network. Only
the A chain of the protein, including the specified water molecules,
was retained after processing. The His447 residue was manually
set to a mono-protonated state. Residues with unmodelled side
chain atoms were predicted using Prime [63].
Docking in FRED [39]. The receptor file was prepared in FRED
receptor [64] in which the binding site was defined by a box with a
Figure 7. Predicted binding poses of both C5685 enantiomers
by molecular docking simulations. Poses of C5685 (R) and C5685
(S) that were generated using the modified parameter settings in Glide
are shown with carbons colored white and yellow, respectively. The
part of C5685 as modeled in the X-ray crystal structure is shown with
carbons colored in cyan, and the 12 conserved water molecules that
were included in the docking simulations are indicated in red.
doi:10.1371/journal.pone.0026039.g007
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and 1453 A ˚ 3, respectively. Conformational ensembles of the
ligands used as input were generated in OMEGA [65], and
docking was performed using default parameter settings.
Docking in Glide [40,66]. The receptor grid was prepared
from the command line using default settings except for the
dimensions of the ligand diameter midpoint box and the enclosing box, for
which the side lengths were increased to 20 A ˚ and 35 A ˚,
respectively. The binding site was defined from the x-, y-, z-
coordinates 31.30, 22.70, and 9.80, respectively. Docking was
performed in standard precision mode using either default settings
or modified parameter settings (increasing the number of poses to
include during the post-docking minimization and the number of
output poses to 1000 and 100 per ligand, respectively).
Docking in GOLD [41,67,68]. The binding site was defined
as a radius of 15 A ˚ from the hydroxyl oxygen of Tyr337. The 12
water molecules included in the coordinate file were active and
allowed to spin during the docking simulation. Docking was
performed using default parameter settings. The pose ranked
highest by GoldScore was considered from the docking.
Evaluation of output poses. RMSD values (A ˚) of the heavy
atoms of the generated poses compared to the crystallographically
determined ligand conformations were calculated in MOE
[57,69]. RMSD values for the two C5685 enantiomers were
based on the part of the ligand that was modeled and included in
the final C5685NmAChE structure (i.e. excluding the atoms of the
N-ethylpyrrolidine moiety, see File S1). To enable RMSD
calculations for all included ligands, the atomic coordinates of
the protein-ligand complexes were superposed to the
C5685NmAChE protein structure using the protein superpose panel
in MOE [57]. A successfully regenerated binding mode was
defined as having an RMSD value less than 2.0 A ˚. The poses that
were generated using the modified parameter settings in Glide
were scored using twelve scoring functions available in Glide
[40,66], GOLD [41,67,68] and FRED [39] as well as with
Drugscore (version 1.3). The scoring functions include force field-
based (GoldScore), empirical (GlideScore SP, Chemscore [70],
OEChemscore, PLP [71], Screenscore [72]), Gaussian-based
empirical (Chemgauss2, Chemgauss3, Shapegauss [73], Zapbind
[74]) and knowledge-based (DrugScore [75] and ASP [76]). Prior
to re-scoring using Zapbind, the poses generated by Glide were
refined using the Merck Molecular Mechanics Force Field
(MMFF) according to recommendations from OpenEye. The
RMSD values of the poses ranked by Zapbind are reported for the
refined poses.
Calculation of local strain energies. Local strain energies
were calculated in MOE [57] for all poses of C5685 (R) and C5685
(S) generated using the modified parameter settings from Glide
with RMSD values less than 2.0 A ˚. A constrained relaxation of the
docking poses was performed to remove incompatibilities between
the force field used during the docking (OPLS_2001) and the force
field used for the calculations of the potential energies (MMFF94s),
during which all heavy atoms were tethered using a weight of 10.
The docking poses were thereafter fully energy-minimized to the
closest local minima. The local strain energy was calculated as the
difference in potential energy between the relaxed ligand
conformation and the fully energy-minimized conformation. The
same analysis was performed for the ligand conformations
observed in the other determined protein-ligand complexes that
were included in the docking study.
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File S1 Molecular descriptors used in the PCA of small
organic molecules. Re-testing of the representative set
of compounds that were identified as non-binders to
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